Bio-Rad Laboratories, Inc. (BIO)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
As of 01:38PM EST. Market open.
| Previous close | 478.96 |
| Open | 474.38 |
| Bid | 467.63 x 800 |
| Ask | 469.64 x 1400 |
| Day's range | 464.80 - 477.41 |
| 52-week range | 344.63 - 670.62 |
| Volume | |
| Avg. volume | 200,709 |
| Market cap | 13.514B |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.39 |
| Earnings date | 16 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 591.00 |
- Zacks
Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?
Sustained sales gains in terms of the Bio-Rads (BIO) process media, western blotting, Droplet Digital PCR and qPCR products are likely to drive Q4 revenues.
- Business Wire
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
HERCULES, Calif., January 06, 2023--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the fourth quarter and full year 2022 on Thursday, February 16, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
- Zacks
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.
© 2023 Yahoo. All rights reserved.
